Target family: VIP and PACAP receptors (type: gpcr)
Target: VPAC<sub>2</sub> receptor

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.8 pKi
Reference (Journal): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Published in: J Pharmacol Exp Ther

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.9 pEC50
Reference (Journal): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Published in: J Pharmacol Exp Ther

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.3 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.7 pKi
Reference (Journal): Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
Published in: J Pharmacol Exp Ther

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.8 pEC50
Reference (Journal): Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Published in: Mol Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Published in: Eur J Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Published in: Mol Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Published in: Eur J Pharmacol

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.3 pEC50
Reference (Journal): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Published in: J Biol Chem

Ligand: VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Published in: J Biol Chem

Ligand: [125I]VIP (human, mouse, rat) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Published in: J Biol Chem

Ligand: [125I]PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: [125I]BAY 55-9837 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Published in: Diabetes

Ligand: secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pEC50
Reference (Journal): Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Published in: Mol Pharmacol

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Published in: Mol Pharmacol

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: Ro 25-1553 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Published in: Peptides

Ligand: Ro 25-1392 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pEC50
Reference (Journal): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Published in: J Pharmacol Exp Ther

Ligand: Ro 25-1392 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Published in: J Pharmacol Exp Ther

Ligand: PHV (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.2 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PHV (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PHI (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PHI (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PG 99-465 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.7 pIC50
Reference (Journal): Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
Published in: Peptides

Ligand: PG 99-465 (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PG 99-465 (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.3 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PG 99-465 (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 8.4 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PG 97-269 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Published in: Peptides

Ligand: PG 97-269 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.5 pIC50
Reference (Journal): In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Published in: Peptides

Ligand: PG 97-269 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Published in: Mol Pharmacol

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.7 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-38 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.3 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.6 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.4 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.4 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: PACAP-27 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Published in: Diabetes

Ligand: N-stearyl-[Nle17]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Published in: Eur J Pharmacol

Ligand: N-stearyl-[Nle17]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Published in: Eur J Pharmacol

Ligand: N-stearyl-[Nle17] neurotensin-(6-11)/VIP-(7-28) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: maxadilan (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 4.5 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 6 pEC50
Reference (Journal): (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Published in: J Mol Neurosci

Ligand: helodermin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: helodermin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Published in: Ann N Y Acad Sci

Ligand: BAY 55-9837 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Published in: Diabetes

Ligand: BAY 55-9837 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.4 pEC50
Reference (Journal): A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Published in: Diabetes

Ligand: [Arg16]chicken secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: [Arg16]chicken secretin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pIC50
Reference (Journal): Development of high affinity selective VIP1 receptor agonists.
Published in: Peptides

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5 pEC50
Reference (Journal): A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology.
Published in: Neuropharmacology

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.6 pKi
Reference (Journal): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Published in: J Biol Chem

Ligand: [Ala11,22,28]VIP (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 5.9 pEC50
Reference (Journal): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
Published in: J Biol Chem